TY - JOUR
T1 - Mycobacterial infections in adults with haematological malignancies and haematopoietic stem cell transplants
T2 - guidelines from the 8th European Conference on Infections in Leukaemia
AU - European Conference on Infections in Leukaemia group
AU - Bergeron, Anne
AU - Mikulska, Malgorzata
AU - De Greef, Julien
AU - Bondeelle, Louise
AU - Franquet, Tomas
AU - Herrmann, Jean Louis
AU - Lange, Christoph
AU - Spriet, Isabel
AU - Akova, Murat
AU - Donnelly, J. Peter
AU - Maertens, Johan
AU - Maschmeyer, Georg
AU - Rovira, Montserrat
AU - Goletti, Delia
AU - de la Camara, Rafael
AU - Greinix, Hildegard
AU - Slavin, Monica
AU - Hubacek, Petr
AU - Cordonnier, Catherine
AU - Kanerva, Jukka
AU - Herbrecht, Raoul
AU - Lanternier, Fanny
AU - Robin, Christine
AU - Einsele, Hermann
AU - Lehrnbecher, Thomas
AU - Groll, Andreas
AU - von Lilienfeld-Toal, Marie
AU - Pana, Dorothea
AU - Roilides, Emmanuel
AU - Kassa, Csaba
AU - Averbuch, Diana
AU - Engelhard, Dan
AU - Cesaro, Simone
AU - Pagano, Livio
AU - Castagnola, Elio
AU - Compagno, Francesca
AU - Mesini, Alessio
AU - Donnelly, Peter J.
AU - Styczynski, Jan
AU - Botelho de Sousa, Aida
AU - Aljurf, Mahmoud
AU - Navarro, David
AU - Garcia-Vidal, Carol
AU - Ljungman, Per
AU - Paukssen, Karlis
AU - Ammann, Roland
AU - Lamoth, Frédéric
AU - Hirsch, Hans
AU - Ritz, Nicole
AU - Chemaly, Roy
N1 - Publisher Copyright:
© 2022 Elsevier Ltd
PY - 2022/12
Y1 - 2022/12
N2 - Mycobacterial infections, both tuberculosis and nontuberculous, are more common in patients with haematological malignancies and haematopoietic stem cell transplant recipients than in the general population—although these infections remain rare. Mycobacterial infections pose both diagnostic and therapeutic challenges. The management of mycobacterial infections is particularly complicated for patients in haematology because of the many drug–drug interactions between antimycobacterial drugs and haematological and immunosuppressive treatments. The management of mycobacterial infections must also consider the effect of delaying haematological management. We surveyed the management practices for latent tuberculosis infection (LTBI) in haematology centres in Europe. We then conducted a meticulous review of the literature on the epidemiology, diagnosis, and management of LTBI, tuberculosis, and nontuberculous mycobacterial infections among patients in haematology, and we formulated clinical guidelines according to standardised European Conference on Infections in Leukaemia (ECIL) methods. In this Review, we summarise the available literature and the recommendations of ECIL 8 for managing mycobacterial infections in patients with haematological malignancies.
AB - Mycobacterial infections, both tuberculosis and nontuberculous, are more common in patients with haematological malignancies and haematopoietic stem cell transplant recipients than in the general population—although these infections remain rare. Mycobacterial infections pose both diagnostic and therapeutic challenges. The management of mycobacterial infections is particularly complicated for patients in haematology because of the many drug–drug interactions between antimycobacterial drugs and haematological and immunosuppressive treatments. The management of mycobacterial infections must also consider the effect of delaying haematological management. We surveyed the management practices for latent tuberculosis infection (LTBI) in haematology centres in Europe. We then conducted a meticulous review of the literature on the epidemiology, diagnosis, and management of LTBI, tuberculosis, and nontuberculous mycobacterial infections among patients in haematology, and we formulated clinical guidelines according to standardised European Conference on Infections in Leukaemia (ECIL) methods. In this Review, we summarise the available literature and the recommendations of ECIL 8 for managing mycobacterial infections in patients with haematological malignancies.
UR - http://www.scopus.com/inward/record.url?scp=85137784542&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85137784542&partnerID=8YFLogxK
U2 - 10.1016/S1473-3099(22)00227-4
DO - 10.1016/S1473-3099(22)00227-4
M3 - Review article
C2 - 35636446
AN - SCOPUS:85137784542
SN - 1473-3099
VL - 22
SP - e359-e369
JO - The Lancet Infectious Diseases
JF - The Lancet Infectious Diseases
IS - 12
ER -